- Home
- MED vs SKYE Comparison
MED vs SKYE Comparison
Compare MED & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- SKYE
- Stock Information
- Founded
- MED 1980
- SKYE 2012
- Country
- MED United States
- SKYE United States
- Employees
- MED N/A
- SKYE N/A
- Industry
- MED Packaged Foods
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- MED Consumer Staples
- SKYE Health Care
- Exchange
- MED Nasdaq
- SKYE Nasdaq
- Market Cap
- MED 150.7M
- SKYE 121.8M
- IPO Year
- MED N/A
- SKYE N/A
- Fundamental
- Price
- MED $12.91
- SKYE $1.38
- Analyst Decision
- MED Hold
- SKYE Strong Buy
- Analyst Count
- MED 1
- SKYE 5
- Target Price
- MED $16.50
- SKYE $14.75
- AVG Volume (30 Days)
- MED 136.4K
- SKYE 1.8M
- Earning Date
- MED 11-03-2025
- SKYE 11-06-2025
- Dividend Yield
- MED N/A
- SKYE N/A
- EPS Growth
- MED N/A
- SKYE N/A
- EPS
- MED 0.33
- SKYE N/A
- Revenue
- MED $480,449,000.00
- SKYE N/A
- Revenue This Year
- MED N/A
- SKYE N/A
- Revenue Next Year
- MED N/A
- SKYE N/A
- P/E Ratio
- MED $39.16
- SKYE N/A
- Revenue Growth
- MED N/A
- SKYE N/A
- 52 Week Low
- MED $11.57
- SKYE $1.14
- 52 Week High
- MED $21.98
- SKYE $5.96
- Technical
- Relative Strength Index (RSI)
- MED 38.72
- SKYE 27.45
- Support Level
- MED $12.80
- SKYE $1.50
- Resistance Level
- MED $13.48
- SKYE $1.76
- Average True Range (ATR)
- MED 0.40
- SKYE 0.24
- MACD
- MED -0.10
- SKYE -0.18
- Stochastic Oscillator
- MED 19.26
- SKYE 0.00
About MED MEDIFAST INC
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.